<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="other" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Biotherapy</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Biotherapy</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский биотерапевтический журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1726-9784</issn><issn publication-format="electronic">1726-9792</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">18</article-id><article-id pub-id-type="doi">10.17650/1726-9784-2015-14-2-53-58</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>ORIGINAL REPORTS</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="article-type"><subject></subject></subj-group></article-categories><title-group><article-title xml:lang="en">INHIBITION OF MT1-MMP (MMP14) IMPROVES ANT-GLIOMA EFFECT OF COMBINATION: TEMOZOLOMIDE-IONIZING RADIATION IN THE GLIOBLASTOMA CANCER CELLS</article-title><trans-title-group xml:lang="ru"><trans-title>ПОДАВЛЕНИЕ ЭКСПРЕССИИ КЛЕТОЧНОЙ МЕТАЛЛОПРОТЕИНАЗЫ ТИП 14 УСИЛИВАЕТ ПРОТИВООПУХОЛЕВЫЙ ЭФФЕКТ ТЕМОЗОЛОМИДА И ИОНИЗИРУЮЩЕЙ РАДИАЦИИ В КЛЕТКАХ ГЛИОБЛАСТОМ ЧЕЛОВЕКА</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Ulasov</surname><given-names>I. V.</given-names></name><name xml:lang="ru"><surname>Уласов</surname><given-names>Илья Валентинович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><email>ulasov75@yahoo.com</email><xref ref-type="aff" rid="aff1"/><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kaverina</surname><given-names>N. V.</given-names></name><name xml:lang="ru"><surname>Каверина</surname><given-names>Н. В.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Kadagidze</surname><given-names>Z. G.</given-names></name><name xml:lang="ru"><surname>Кадагидзе</surname><given-names>З. Г.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Baryshnikov</surname><given-names>A. Y.</given-names></name><name xml:lang="ru"><surname>Барышников</surname><given-names>А. Ю.</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><xref ref-type="aff" rid="aff2"/></contrib></contrib-group><aff id="aff1"><institution>Центр опухолей головного мозга, Шведский медицинский центр</institution></aff><aff id="aff2"><institution>ФГБНУ «РОНЦ им Н.Н. Блохина»</institution></aff><pub-date date-type="pub" iso-8601-date="2015-06-30" publication-format="electronic"><day>30</day><month>06</month><year>2015</year></pub-date><volume>14</volume><issue>2</issue><fpage>53</fpage><lpage>58</lpage><history><date date-type="received" iso-8601-date="2018-04-10"><day>10</day><month>04</month><year>2018</year></date></history><permissions/><self-uri xlink:href="https://bioterapevt.abvpress.ru/jour/article/view/18">https://bioterapevt.abvpress.ru/jour/article/view/18</self-uri><abstract xml:lang="en"><p>The main goal of our study is to provide clinical and biological assessment of MMP14 as gene that causes recurrent glioblastoma. We analyzed expression of MMP14 in 108 and 129 samples represented by Rembrandt 8РOncomine databases. The biological significance was done is based on genetic knockdown and rescuing of MMP14 attenuated U87 and U251 glioma cells followed by cytofluorimetry and array gene expression. As expected, genetic silencing of MMP14 led to accumulation cells in the “G<sub>2</sub>” phase of cell divisions which correlates to cell kinase’s expression. Furthermore, exposure of MMP14 to ionizing radiation and temozolomidt treatments prolongs glioma cell proliferation and increase the anti-glioma effect of temozolomide-ionizing radiation therapeutic combination. Our data suggest that most of the neoplastic glioma cells express significantly MMP14.Therefore, alteration of MMP14, improves anti-tumor effect.</p></abstract><trans-abstract xml:lang="ru"><p/></trans-abstract><kwd-group xml:lang="ru"><kwd>глиобластома человека</kwd><kwd>MMP14</kwd><kwd>темозоломид</kwd><kwd>glioblastoma multiforme</kwd><kwd>MMP14</kwd><kwd>Temozolomide</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Брюховецкий И.С., Брюховецкий А.С., Мищенко П.В., Хотимченко Ю.С. Роль системных механизмов миграции и хоуминга стволовых клеток в развитии злокачественных опухолей центральной нервной системы и разработка новых методов противоопухолевой терапии // Российский биотерапевтический журнал. - 2013. - Т. 12, № 4. - С. 3-12.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Степанова Е.В., Зейналова К.Р. Механизмы резистентности к трантузумабу // Российский биотерапевтический журнал. - 2011. - Т. 10, № 4. - С. 3-8.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Уласов И.В., Каверина Н.В., Кадагидзе З.Г., Барышников А.Ю. Антиглиомная аденовирусная виротерапия: механизм, регуляция и клинические перспективы // Российский биотерапевтический журнал. - 2014. - Т. 13, № 2. - С. 11-8.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Banerjee N.S., Rivera A.A., Wang M. et al. Analyses of melanoma-targeted oncolytic adenoviruses with tyrosinase enhancer/promoter-driven E1A, E4, or both in submerged cells and organotypic cultures // Mol Cancer Ther. - 2004. - 3(4). - P. 437-49.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Fernandez-Vidal A., Ysebaert L., Didier C. et al. Cell adhesion regulates CDC25A expression and proliferation in acute myeloid leukemia // Cancer Res. - 2006. - 66(14). - P. 7128-35.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Groves M.D., Puduvalli V.K., Hess K.R. et al. Phase II trial of temozolomide plus the matrix metalloproteinase inhibitor, marimastat, in recurrent and progressive glioblastoma multiforme // J Clin Oncol. - 2002. - 20(5). - P. 1383-8.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Hagemann C., Anacker J., Ernestus R.I., Vince G.H. A complete compilation of matrix metalloproteinase expression in human malignant gliomas // World J. Clin. Oncol. - 2012. - 3(5). - P. 67-79.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Kim J.H., Bae Kim Y., Han J.H. et al. Pathologic diagnosis of recurrent glioblastoma: morphologic, immunohistochemical, and molecular analysis of 20 paired cases // Am. J. Surg. Pathol. - 2012. - 36(4). - P. 620 8.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Lehti K., Allen E., Birkedal-Hansen H. et al. An MT1-MMP-PDGF receptor-beta axis regulates mural cell investment of the microvasculature // Genes Dev. - 2005. - 19(8). - P. 979-91.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Levin V.A., Phuphanich S., Yung W.K. et al. Randomized, double-blind, placebo-controlled trial of marimastat in glioblastoma multiforme patients following surgery and irradiation // J Neurooncol. - 2006. - 78(3). -P. 295-302.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Li R., Li G., Deng L. et al. IL-6 augments the invasiveness of U87MG human glioblastoma multiforme cells via up-regulation of MMP-2 and fascin-1 // Oncol Rep. - 2010. - 23(6). - P. 1553-9.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Ulasov I., Yi R., Guo D. et al. The emerging role of MMP14 in brain tumorigenesis and future therapeutics // Biochim Biophys Acta. - 2014. - 1846(1). - P. 113-20.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Saini D., Shelke S., Mani Vannan A. et al. Transcription profile of DNA damage response genes at G(0) lymphocytes exposed to gamma radiation // Mol Cell Biochem. - 2012. - 364(1/2). - P. 271-81.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Ulasov I., Thaci B., Sarvaiya P. et al. Inhibition of MMP14 potentiates the therapeutic effect of temozolomide and radiation in gliomas // Cancer Med. - 2013. -2(4). - P. 457-67.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Wang H., Wang S., Shen L. et al. Chk2 down-regulation by promoter hypermethylation in human bulk gliomas // Life Sci. - 2010. - 86(5/6). - P. 185-91.</mixed-citation></ref></ref-list></back></article>
